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Abstract
The association between stimulant drug use and aberrant reward processing is well-documented in the literature, but
the nature of these abnormalities remains elusive. The present study aims to disentangle the separate and interacting
effects of stimulant drug use and pre-existing familial risk on abnormal reward processing associated with stimulant
drug addiction. We used the Monetary Incentive Delay task, a well-validated measure of reward processing, during
fMRI scanning in four distinct groups: individuals with familial risk who were either stimulant drug-dependent (N= 41)
or had never used stimulant drugs (N= 46); and individuals without familial risk who were either using stimulant drugs
(N= 25) or not (N= 48). We ﬁrst examined task-related whole-brain activation followed by a psychophysiological
interaction analysis to further explore brain functional connectivity. For analyses, we used a univariate model with two
ﬁxed factors (familial risk and stimulant drug use). Our results showed increased task-related activation in the putamen
and motor cortex of stimulant-using participants. We also found altered task-related functional connectivity between
the putamen and frontal regions in participants with a familial risk (irrespective of whether they were using stimulant
drugs or not). Additionally, we identiﬁed an interaction between stimulant drug use and familial risk in task-related
functional connectivity between the putamen and motor-related cortical regions in potentially at-risk individuals. Our
ﬁndings suggest that abnormal task-related activation in motor brain systems is associated with regular stimulant drug
use, whereas abnormal task-related functional connectivity in frontostriatal brain systems, in individuals with familial
risk, may indicate pre-existing neural vulnerability for developing addiction.
Introduction
A change in our understanding of drug addiction as a
brain disorder was inﬂuenced by the notion that drug
addiction was not a deﬁcit of character, but rather the
result of aberrant brain function caused by excessive drug
use1. A prominent hypothesis has been that drugs of
abuse alter reward processing through disruption of the
mesolimbic dopamine reward system – a theory that has
since been supported by both animal models and human
research2. The brain reward system assimilates both top-
down and bottom-up inputs from cortical and subcortical
brain circuitry, including prefrontal and motor cortical
systems, to support the integrated evaluation of environ-
mental stimuli3. Dysregulation of the mesolimbic dopa-
mine reward system has been associated with both acute
and chronic use of stimulant drugs4,5, leading to changes
in how drug users perceive and process reward. These
changes hypothetically facilitate the development and
maintenance of addiction6,7.
However, the notion that drug use is the sole cause of
aberrant reward processing in addicted individuals is
disputable. Evidence indicates that stimulant drug users
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with a family history of substance abuse are eight times
more likely to develop an addiction than those without a
family history8. Familial transmission of substance use
disorders suggests pre-existing genetic9,10, sociological,
economic, and other environmental risk factors that are
often shared between biological ﬁrst-degree relatives (i.e.,
familial risk-factors). Accordingly, healthy ﬁrst-degree
relatives of individuals affected by addiction report a
number of abnormalities in terms of personality traits and
brain structure11,12, aberrant striatal dopamine neuro-
transmission13–15, and altered striatal function during
reward processing16,17. Thus, pre-existing familial vul-
nerability renders the individual vulnerable to developing
addiction should they start taking drugs18–23. Likewise,
stimulant drugs also exert effects that contribute to
aberrant reward processing and problematic drug use24,25.
The potential contribution of both familial and drug
use-related risk factors makes it difﬁcult to determine the
cause of aberrant reward processing associated with sti-
mulant drug use. Here, we investigated the effects of sti-
mulant drug use and familial risk within a single statistical
model to determine their possible separate and interacting
effects on reward processing. To identify the effects of
familial risk we examined candidate endophenotypes
based on neural network activation patterns. Endophe-
notypes are stable, heritable, and quantiﬁable traits
observed in both clinically affected individuals and their
unaffected ﬁrst-degree relatives26. Hypothetically, endo-
phenotypic abnormalities, arising from genetic, socio-
logical, economic, and other environmental risk-factors
common between biological ﬁrst-degree relatives (i.e.,
familial risk-factors), both subserve and predate the
development of stimulant drug addiction.
To identify endophenotypes in the current study, we
included fully-related siblings who not only share
approximately 50% of their genes, but also childhood
sociological, economic, and other familial risk-factors,
which may inﬂuence the development of addiction27,28.
These individuals are of particular interest not only
because of their increased familial risk of developing
addiction but also because of their success in avoiding the
initiation of stimulant drug use despite the increased risk,
potentially indicating compensatory or resiliency
mechanisms. This endophenotype approach has been
used previously in addicted populations11,12,29,30, although
not in relation to reward processing. To identify effects of
stimulant drug use as well as the familial risk of addiction
within the same model, we included non-dependent sti-
mulant drug users and non-drug users, both without
familial risk, in addition to the sibling pairs with familial
risk. Together, the four distinct groups each possessed a
unique combination of familial and stimulant drug-
related risk-factors, allowing the disentanglement of the
distinct and interacting effects of both stimulant drug use
and familial risk. By investigating interacting effects, we
may gain insight into possible compensation or resiliency
in at-risk individuals, such as those with familial risk who
successfully avoided stimulant drug use, and those who
use stimulant drugs but successfully avoid the develop-
ment of addiction.
Although the risk associated with the development of
addiction may not be drug-speciﬁc, we deliberately
focused on stimulant drugs given their critical depen-
dence on the mesocorticolimbic dopamine system31,32
and the hypothesized association between the drug-
induced release of dopamine and the drug’s addictive
liability33. The abuse liability of stimulant drugs and the
relative high heritability, which has been estimated to be
0.7233, suggest that individual variations in behaviorally
relevant neural networks may mediate the individual’s
susceptibility to drug addiction33.
We examined neural responses to reward using the
monetary incentive delay (MID) task—a well-validated
paradigm for examining anticipatory brain responses to
reward34,35. The MID-task has been associated with
abnormal activation in frontostriatal circuits in drug users
and those at-risk for addiction; however, these results
have been inconsistent25 and often focus on regions of
interest rather than the whole brain. More importantly,
prior studies have not addressed the critical question of
causality. To address this question in stimulant drug
addiction, we hypothesized that if aberrant reward pro-
cessing is a consequence of stimulant drug use, then
participants with a personal history of stimulant drug use
will show altered task-related striatal function during
reward processing. Alternatively, if aberrant reward pro-
cessing is a pre-existing vulnerability resulting from
familial risk, then fully-related sibling pairs will share a
similar pattern of abnormal task-related striatal function
during reward processing distinct from that of unrelated
control participants.
Materials and methods
Study sample
A total of 165 participants were recruited for this study
from local treatment centers, by media advertisements, or
by word-of-mouth within the community. All participants
were between the age of 18–55 years and ﬂuent in written
and spoken English. Participants also underwent semi-
structured interviews to ascertain personal and family
history of drug/alcohol addiction, physical health
(including signs of acute intoxication and withdrawal),
and mental health as assessed with the Structured Clinical
Interview for DSM-IV-TR Axis I Disorders36. Participants
were split into four groups based on their individual
familial risk (F) and stimulant drug-related risk (S).
Stimulant-dependent individuals (F+S+) and their unaf-
fected siblings (F+S−) composed the groups with familial
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risk. Non-dependent stimulant drug users without a
family history of addiction (F−S+) and individuals with-
out either family or personal history of drug addiction
(F−S−) composed the control groups without familial
risk (see Table 1).
All F+S+ participants were required to satisfy the
DSM-IV-TR criteria37 for stimulant drug dependence
(cocaine: 92.7%; amphetamines: 7.3%) and share both
biological parents with an F+S− sibling who was also able
to participate in the study. Additionally, F−S+ control
participants were required to have engaged in regular
stimulant drug use for at least two years but had never
developed addiction to drugs or alcohol and had never
been prescribed stimulant drugs for medical reasons. We
intentionally recruited non-dependent stimulant drug-
using controls because their lack of dependence reduced
their likelihood of possessing those familial risk factors
and associated neural vulnerabilities that render indivi-
duals susceptible to addiction. The sample size was
determined by power analysis, establishing a group size of
N= 42 for 95% power to identify the effects of familiarity.
Semi-structured interviews determined that control par-
ticipants had no ﬁrst-degree relative affected by addiction.
For all groups, exclusionary criteria included a lifetime
history of a psychotic, neurological, or neurodevelopment
disorder, or traumatic head injury. Exclusion criteria for
unaffected siblings and unrelated controls also included
any personal history of substance addiction (except
nicotine). Concurrent drug and alcohol consumption for
these three groups were low (as reﬂected by the Alcohol
Use Disorders Identiﬁcation Test [AUDIT] and Drug
Abuse Screening Test [DAST-20] scores, see Table 1).
Experience with tobacco and nicotine have been reported
in all groups (see Table 1). Group differences in reported
nicotine (χ2= 67.04, p < 0.001) and cannabis use (χ2=
104.36, p < 0.001) between stimulant drug users and non-
users were controlled for in a separate post-hoc analysis.
Critically, although drug-taking experiences are common
in people with familial risk38, F+S− participants in the
present study did not report stimulant drug use. Exclusion
criteria were kept deliberately minimal as minor psycho-
pathology may be a clinical marker of vulnerability and an
Table 1 Demographics, personality, clinical and MID-task performance data for all participants
F–S− No
familial risk; No
stimulant use
(N= 48)
F−S+ No
familial risk;
Stimulant use
(N= 25)
F+S− Familial
risk; No
stimulant use
(N= 46)
F+S+ Familial risk;
Stimulant use (N= 41)
Mean (±SD) Mean (±SD) Mean (±SD) Mean (±SD)
Demographics
Age (years) 32.5 ( ± 8.8) 28.6 (±6.6) 32.3 (±8.4) 34.6 (±7.4)
Gender (% male) 63% 52% 48% 90%
Disposable income (£/month) 660 (±940) 714 (±1154) 403 (±411) 399 (±672)
Trait Impulsivity (BIS-11 total score) 59.3 (±7.6) 63.2 (±10.4) 67.2 (±10.4) 77.0 (±9.4)
Alcohol consumption (AUDIT total score) 3.2 (±2.3) 5.8 (±1.5) 3.9 (±4.6) 11.7 (±11.9)
Drug-taking experiences (DAST-20 total score) 0.0 (±0.0) 2.4 (±1.0) 0.5 (±1.1) Not completed
Compulsive use of stimulants (OCDUS total score) - - 1.2 (±1.7) - - 23.6 (±9.3)
Nicotine Use (current/past) 12.5% 43.8% 68% 16% 54% 37% 92.7% 4.9%
Cannabis Use (current/Past) 0% 20.8% 36% 60% 8.7% 65.2% 65.9% 34.1%
Task performance
Money gained (£) 8.65 (±1.2) 8.46 (±1.2) 8.48 (±1.2) 8.49 (±1.5)
Successful responses to neutral trials (number) 12.4 (±2.1) 12.1 (±1.8) 12.1 (±2.4) 10.2 (±3.1)
Successful responses t rewarding trials (number) 27.9 (±3.4) 28.6 (±2.9) 27.8 (±3.6) 27.9 (±4.9)
Response time for successful neutral trials (ms) 210.6 (±23.7) 206.7 (±22.4) 211.5 (±23.1) 220.6 (±40.1)
Response time for successful rewarding trials (ms) 204.5 (±19.0) 200.8 (±19.7) 208.3 (±21.2) 207.0 (±25.8)
Data are displayed by individual group status. Standard deviation (SD) shown in parentheses. [Notes: AUDIT score > 8 indicate harmful drinking. DAST-20 < 5 indicate
recreational use of drugs in general (not speciﬁc to stimulant drugs). The DAST-20 test was not administered in dependent stimulant users as it is not sensitive to
clinical populations
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important characteristic of the participant in the familial
risk group. Further details can be found in the supple-
mentary material (SM).
In addition to stimulant drug dependence, 12 F+S+
participants further met diagnostic criteria for alcohol
dependence, and 22 F+S+ participants for opioid
dependence. Consistent with prior literature39,40, partici-
pants with familial risk reported a high prevalence of
childhood adversity when compared with control parti-
cipants (F1,159= 29.12, p < 0.001), as determined by
Childhood Trauma Questionnaire (CTQ) abuse
scores11,41. Differences in familial relationship between
sibling pairs and unrelated control groups (i.e., sibling
pairs with familial risk were related, whereas control
participants without familial risk were not) was investi-
gated post-hoc. Prior to testing, stimulant-positive urine
samples were provided by all except three F+S+ partici-
pants, indicating the use of stimulant drugs in the last
72 h42. Drug-negative urine samples were provided by all
other participants. This study was approved by the NHS
Cambridgeshire2 Research Ethics Committee (08/H0308/
310PI:KDE), and written informed consent was obtained
from all participants prior to study enrollment. This
sample is described in more detail in the SM; separate
data from this sample have been published pre-
viously11,12,43–48.
MID-task design
We used the MID-task49 to examine the neural corre-
lates of reward anticipation (Fig. 1). The task consisted of
three phases: anticipation, target, and feedback. A cue
presented in the anticipation phase notiﬁed participants of
the potential to receive a monetary or neutral reward. The
target stimulus, presented following the anticipation
phase, prompted participants to respond by pressing a
button. Finally, during the feedback phase participants
were informed about the outcome of their behavioral
response.
During the anticipatory phase, three cues, indicating
either a neutral or rewarding outcome, were randomly
displayed (Fig. 1). The anticipatory cue was presented for
250ms, notiﬁed participants of the potential to win a
monetary or a neutral reward, and was followed by a jit-
tered black anticipation screen for 3000–5000 ms. The
target stimulus, always a white square, was then presented
for 100–400 ms, during which the participant had to
respond by pressing a button. Immediately following the
target stimulus, either successful or unsuccessful feed-
back, contingent on participant response, was presented
for 1650 ms. Feedback screens were followed by a ﬁxation
cross screen, which was presented for 5000–2700ms until
the next trial commenced. Responses were deemed suc-
cessful if performed during presentation of the target on
the screen. The time between the presentation of the cue
and the target stimulus represents the anticipatory
phase50, during which neural responses were recorded
(Fig. 1).
Prior to scanning, all participants underwent 66 training
trials to ensure they had a clear understanding of how to
complete the task. Participants were told prior to scan-
ning that their total earnings were contingent upon task
performance. The duration of the anticipation phase was
Fig. 1 Schematic representation of the MID-paradigm depicting screen sequence, contrast used, and key performance variable intervals.
The sequence presented screens including an anticipatory cue, inter-stimulus (IS) interval, target stimulus, feedback, and ﬁxation cross. The neutral
cue (no reward) was represented by an empty circle, the small gain (10 pence) cue was represented by a circle transected by a single horizontal line,
and the large gain (50 pence) cue was represented by a circle transected by two horizontal lines. Successful feedback was depicted by an image of a
10p or 50p coin with the words “you’ve won 10p!” and “you’ve won 50p!” respectively (depending on the magnitude of the previous anticipation
cue). Unsuccessful feedback (too late or too early) and successful neutral reward feedback, was depicted as an empty circle with the words “you’ve
won 0p!”
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based on participants’ performance to maintain a 66%
success rate. In total, 66 trials were completed by each
participant. Participants also completed an additional, but
separate version of this task, which included drug-related
cues, the results of which are not reported here.
Statistical analysis
Behavioral data were analyzed using the Statistical
Package for Social Science (SPSS v.22; IBM Chicago,
Illinois). We employed a univariate analysis of variance
model with two ﬁxed between-subject factors: familial
risk (participants with and without addiction in the
family) and stimulants (participants with and without
stimulant drug use). This statistical model allowed the
separate investigation of familial risk and stimulant drug
use as well as possible interactions between these two
factors. Analyzing distinct and interacting effects within
the same model not only mitigates Type I error but can
also reveal interactions between these two factors. This is
particularly important as the development of addiction is
likely contingent on both the use of drugs and familial
risk-factors28,51.
Gender and monthly disposable income were included
as covariates in all analyses due to their reported invol-
vement in reward processing and the development of
addiction52,53, and to control for group differences (gen-
der: χ2= 7.01, p= 0.008, income: F1,155= 5.40, p= 0.021).
These differences were driven by male dominance in the
F+S+ group and less monthly disposable income in
participants with familial risk, irrespective of drug use.
Participants with less money to spend demonstrated
decreased response times (r=−0.18, p= 0.022). Given
that age did not differ between groups (F3,155= 2.60, p=
0.054) and was not correlated with outcome measures, it
was not used as a covariate.
We controlled, post-hoc, for the potentially confound-
ing differences in the severity/duration of drug use
between the two stimulant using groups, and the different
relationships between participants in the groups with and
without familial risk. Accordingly, we subjected the sig-
niﬁcant neuroimaging results to a one-way ANCOVA
analysis by importing mean cluster beta values (i.e., mean
activation or connectivity values) into SPSS. To control
for differences in drug-taking experiences, we entered the
following variables as covariates: severity of stimulant use
(OCDUS score), years of stimulant drug use, alcohol
consumption (AUDIT score), current/past nicotine use,
and current/past cannabis use. To control for the shared
environment of the sibling pairs, we further included a
measure of childhood adversity (CTQ abuse score) as a
covariate in the same post-hoc ANCOVA model. We did
not include these variables as covariates in the main
analysis to avoid statistically controlling for aspects that
were critical in deﬁning the groups54.
Behavioral data were analyzed for accuracy and latency
of successful trials, and the total amount of money gained
using a repeated-measures ANCOVA model with trial
type (monetary versus neutral reward) as the within-
subject factor and stimulants and familial risk as the two
between-subject factors. Square-root transformation was
used for best normalization. Sidak post-hoc analysis was
used for all individual group comparisons. Accordingly,
demographic data were analyzed using a general linear
model (GLM) with stimulants and familial risk as ﬁxed
factors. Demographic and task performance data were
used for analyses (see Table 1). Pearson correlation
coefﬁcients were calculated to assess the relationships
between outcome measures. We also examined the rela-
tionship between self-reported impulsivity and task-
related neural activation and functional connectivity
using the Barratt Impulsiveness Scale (BIS-11). All tests
were two-tailed and signiﬁcance levels of p < 0.05 were
assumed.
Neuroimaging data acquisition and analysis
Further details on neuroimaging data acquisition and
analysis can be found in the SM. Brieﬂy, neuroimaging
data were acquired at the Wolfson Brain Imaging Centre,
University of Cambridge, in one run on a Siemens TIM-
Trio 3-Tesla scanner (Siemens Medical Solutions, Erlan-
gen, Germany). The scans were analyzed in FMRIB’s
Software Library (FSL, v-5.0.9, https://fsl.fmrib.ox.ac.uk/
fsl) and consisted of two main stages: (1) task activation
analysis to identify brain regions involved in reward
processing and effects of interest (i.e., main effects of
familial risk, stimulant drug use, and their interaction); (2)
post-hoc psychophysiological interaction (PPI) analysis to
further explore functional connectivity related to reward
anticipation and effects of interest.
Following standard pre-processing procedures, statis-
tical analyses were conducted at the ﬁrst and second levels
by using fMRI Expert Analysis Tool. At the ﬁrst level,
GLM analysis was conducted for each participant. As
reward magnitude showed no behavioral differences in
latency, accuracy, or brain activation, small and large
rewards were collapsed resulting in a single monetary
reward type. Contrasts of interest included: anticipation of
monetary reward versus neutral reward, successful feed-
back, and unsuccessful feedback (results on feedback are
reported in the SM), consistent with prior literature34,35.
At the second level, the main effect of each contrast
collapsed across groups was computed using one-sample
t-tests, with gender and monthly disposable income as
covariates, to reveal task activation patterns. The
ANCOVA model was used to assess main effects of sti-
mulants and familial risk in the four groups as well as
their interaction for each contrast. In the second stage,
owing to observed task-related activation in the putamen,
Just et al. Translational Psychiatry            (2019) 9:65 Page 5 of 12    65 
post-hoc exploratory PPI analysis was used between
striatal seed regions of interests (ROI) and whole brain.
The seed ROI was deﬁned by the peak coordinates of the
signiﬁcant putamen cluster extracted from a group level
with a 4 mm radius. For all analyses, signiﬁcant effects
were deﬁned, after voxelwise testing and family-wise error
(FWE) correction for multiple comparison, as clusters
with a voxel height of Z > 2.58 (i.e., p < 0.005) and cluster-
corrected p-value of 0.00015 (using FSL’s easythresh
function). Due to recent discussions regarding the control
of false positives in cluster inference55, we employed a
relatively more stringent threshold than the conventional
Z > 2.3 (i.e., p < .01).
Of the nine participants that were excluded post-hoc,
ﬁve were due to excessive head motion during scanning (1
F−S−, 3 F+S+, 1 F+S−), one due to poor data quality (1
F+S−), and three due to incomplete behavioral data (1 F
+S+, 1 F+S−, 1 F−S+), resulting in a remaining
sample of 160 participants. Baseline demographic char-
acteristics did not differ between excluded and included
participants.
Results
Task performance
In keeping with the MID-task design to minimize
behavioral differences, we did not ﬁnd a main effect of
familial risk or stimulants on performance measures
(Table 1). However, since the MID-task included both
monetary and neutral reward trials, we analyzed, post-
hoc, the effect of trial valence on accuracy and latency of
successful trials. In accordance with prior work, we
observed across all groups, a main effect of trial valence
on the number of successful responses (F1,155= 218.55, p
< 0.001), and mean response times (F1,155= 22.23, p <
0.001; Fig. 2), such that participants responded faster and
with more accuracy to the prospect of a monetary reward
compared with a neutral reward. Detailed performance
data are summarized in Table 1.
Task-related brain activation
All signiﬁcant clusters resulting from the whole brain
neuroimaging analysis are reported in Table 2. Results
describe brain function during reward anticipation and
are reported at cluster-corrected levels using the afore-
mentioned thresholds (see Methods for details). Con-
sistent with prior work25, the MID-task activated reward-
related regions in all participants. Signiﬁcant clusters of
task-related activation encompassed the ventromedial
orbitofrontal cortex (OFC) and occipital pole, extending
to the paracingulate gyrus, anterior cingulate cortex
(ACC), insula, pallidum, striatum, and thalamus (Fig. 3a;
Table 2).
Whole brain neuroimaging analysis revealed signiﬁcant
main effects of both stimulant drug use and familial risk on
task-related brain activation. We observed a main effect of
stimulants in the bilateral precentral gyri, right supra-
marginal gyrus, and bilateral putamen. This effect was due
to increased activation in these regions in stimulant drug
users when compared with non-users (Fig. 3b). Notably,
peak putamen clusters were located in the dorsolateral
part of the putamen (MNI-coordinates x, y, z: 26, −12, 10
and −24, 0, 10)56. We also observed a main effect of
familial risk in the left occipital pole, which was driven by
greater task-related activation in participants without
familial risk compared with participants with familial risk
(Table 2). We observed no interaction between stimulants
and familial risk in task-related brain activation.
Following the whole brain neuroimaging analysis, we
subjected all signiﬁcant clusters (Table 2) to an additional
post-hoc analysis to address potentially confounding fac-
tors regarding drug-taking experiences and familial risk.
The signiﬁcant main effect of stimulants in the
bilateral precentral gyri (right: F1,158= 6.07, p= 0.015;
left: F1,158= 7.76, p= 0.006), right supramarginal gyrus
(F1,158= 6.35, p= 0.013), and bilateral putamen (right:
F1,158= 14.72, p < 0.001; left: F1,158= 8.17, p= 0.005), and
the main effect of familial risk in the left occipital pole
(F1,158= 8.32, p= 0.005), all survived this additional post-
hoc analysis.
Task-related brain functional connectivity
In view of the main effect of stimulants on task-related
activation of the bilateral putamen and the purported role
of the putamen in drug addiction57, we performed a PPI
analysis to further explore the role of this region in reward
anticipation. The GLM analysis, which used both stimu-
lants and familial risk as the ﬁxed factors, when
Fig. 2 Mean response latency in anticipation of monetary and
neutral rewards. All participantes responded faster in anticipation of
monetary reward compared to neutral reward
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conducted on PPI results, revealed an effect of familial
risk on putamen functional connectivity strength to the
right medial prefrontal cortex (mPFC), frontal pole, right
ACC, left temporal lobe extending into the OFC, and
brainstem. These results reﬂected increased putamen
functional connectivity to the frontal pole, temporal pole,
and brainstem, and decreased putamen functional con-
nectivity to the ACC in individuals with familial risk
compared with those without familial risk (Fig. 3c, Table
2). In addition to the main effect of familial risk, an effect
of stimulants was observed in functional connectivity
strength between the putamen and the right middle
frontal gyrus/superior frontal gyrus, such that stimulant
drug users showed decreased functional connectivity in
this pathway (Table 2).
We also observed an interaction between familial risk
and stimulants on putamen functional connectivity to the
bilateral precentral gyrus, bilateral lateral occipital cortex,
and right postcentral gyrus. The interaction effect was due
to increased putamen functional connectivity in F−S+
participants and F+S− participants when compared with
F+S+ and F–S– participants (Table 2).
Like the previous neuroimaging analysis, we subjected
all signiﬁcant clusters resulting from the PPI analysis to an
additional post-hoc analysis to control for potentially
confounding effects resulting from variations in stimulant
drug-taking experiences and familial risk across the
groups. These additional post-hoc analyses conﬁrmed a
signiﬁcant main effect of familial risk in functional con-
nectivity between the putamen and the right mPFC (F1,158
= 6.88, p= 0.010), frontal pole (F1,158= 11.01, p= 0.001),
right ACC (F1,158= 7.31, p= 0.008), left temporal lobe
extending to the OFC (F1,158= 18.31, p < 0.001), and
brainstem (F1,158= 6.02, p= 0.015). However, the main
effect of stimulants, encompassing the middle frontal
gyrus (F1,158= 2.54, p= 0.113) and superior frontal gyrus
(F1,158= 3.63, p= 0.059), did not reach signiﬁcance.
The signiﬁcant familial risk-by-stimulant interaction
effects in functional connectivity between the putamen
and the bilateral precentral gyrus (Right: F1,158= 12.96,
p < 0.001; Left: F1,158= 12.07, p= 0.001), occipital cortex
(Right: F1,158= 16.77, p < 0.001; Left: F1,158= 18.33, p=
0.005), and right postcentral gyrus (F1,158= 14.38, p <
0.001) all survived additional post-hoc analyses.
No measures of task-related neural activation or func-
tional connectivity were related to self-reported impulsivity,
as measured by BIS-11 total score (p > 0.05; see Table S1).
Discussion
The aim of the study was to disentangle the distinct and
interacting effects of stimulant drug use and familial risk
on reward processing. Risk associated with stimulant drug
use encompasses both pre-existing factors related to the
initiation of stimulant use and the effects of regular sti-
mulant use. In contrast to previous studies, which inves-
tigated these effects separately, often using region of
interest approaches, we examined these effects within a
Table 2 Peak Z-values and MNI-coordinates.
Brain region BA Peak Z-
value
Peak coordinates
x y z
A. Task-related activation
Anticipation condition
Task activation
Orbital frontal cortex* 13 5.98 30 22 −10
Occipital pole 18 7.41 −22 −96 4
Stimulant use > no stimulant use
Right dorsolateral putamen - 3.49 26 −12 10
Left dorsolateral putamen - 3.52 −24 0 10
Right precentral gyrus 8 4.32 42 4 34
Left precentral gyrus 6/4 3.87 −34 −8 42
Right supramarginal gyrus 7 4.37 40 −44 40
Familial risk < no familial risk
Occipital pole 18 3.76 −2 −94 −16
B. Task-related putamen connectivity
Stimulant use < no stimulant use
Middle frontal gyrus 8 4.04 44 12 40
Superior frontal gyrus 6 3.33 −22 4 56
Familial risk > no familial risk
Medial frontal cortex 10 3.52 2 50 −10
Frontal Pole 10 3.55 40 50 −8
Temporal pole 36 3.84 −20 4 −28
Brainstem - 3.68 8 −24 −30
Familial risk < no familial risk
Anterior cingulate cortex 24 3.45 4 −2 38
Stimulant use X familial risk
Left precentral gyrus 4 4.38 −38 −14 48
Right precentral gyrus 6 3.64 30 −4 50
Postcentral gyrus 4/1 4.38 66 −6 30
Lateral occipital cortex 19 3.70 −18 −88 30
Lateral occipital cortex 19 3.59 26 −68 32
Regions are listed in order of cluster size from largest to smallest. (A) Summary
of fMRI results for the monetary MID-condition. (B) PPI results showing the
difference in functional connectivity with a seed in the bilateral putamen (MNI-
coordinates: 26, −12, 10, and −24, 0, 10) during the reward anticipation
BA Broadmann Area
*This cluster extended to the paracingulate gyrus, anterior cingulate cortex
(ACC), insula, pallidum, striatum, and thalamus
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single model in the whole brain. Using this approach, we
found that although task performance did not differ
between groups, involvement of underlying corticostriatal
circuitries indicated possible vulnerability and resilience
factors related to stimulant drug addiction.
We found signiﬁcantly increased task-related activation
in the dorsolateral putamen, a region implicated in motor
control58, rather than the ventral striatum, which is
associated with reward processing and reinforcement.
Regular use of stimulant drugs was signiﬁcantly associated
Fig. 3 Brain function during the anticipation of monetary reward versus neutral reward. Yellow depicts relatively greater changes in activation
or functional connectivity. Z-coordinates represented in MNI space. a MID-task activation across all groups. Thresholded statistical map shown (p <
0.00015; FWE corrected for multiple comparisons). b Effect of stimulant drug use on task-related brain activation. Thresholded statistical map showing
areas of increased activation in stimulant drug users compared with non-users (p < 0.00015; FWE corrected for multiple comparisons). c Effect of
familial risk on putamen functional connectivity to the whole brain. Thresholded statistical map showing areas of altered functional connectivity in
familial groups compared with non-familial groups (p < 0.00015; FWE corrected for multiple comparisons)
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with increased task-related activation in motor circuitry.
By contrast, familial risk was associated with altered
corticostriatal functional connectivity between the puta-
men and brain regions implicated in reward processing,
speciﬁcally the mPFC, OFC, and ACC. We also identiﬁed
an interaction between familial risk and stimulant drug
use in functional connectivity strength for the putamen
and precentral and postcentral gyri, such that at-risk
individuals (due to either familial risk or stimulant drug
use) who did not develop addiction, showed increased
functional connectivity strength within these regions.
Together, our ﬁndings indicate that the two risk factors
associated with stimulant drug use, i.e., familial and
stimulant-related risk, are reﬂected by distinct functional
brain changes during reward anticipation.
Effects of stimulant drug use on reward processing
Although stimulant drug use was associated with dif-
ferences in brain activation, it had no behaviorally mea-
surable effects on MID-task performance. There are
several approaches to interpreting neuroimaging ﬁndings
not reﬂected in behavioral task performance59. Given that
the MID-task was designed to preclude behavioral dif-
ferences34, our ﬁndings may suggest underlying cognitive
abnormalities that cannot be attributed to non-speciﬁc
performance measures60. At a neural level, during an
anticipatory period preceding a correct response, we
identiﬁed in stimulant drug users compared with non-
drug users, signiﬁcantly increased task-related brain
activation in the putamen and motor cortex (Fig. 3b)—
brain regions implicated in motor response. Such activa-
tions in motor pathways during MID-task performance
and cue-reactivity have been frequently reported in pub-
lished work25,31,61–66, and are unsurprising given conver-
ging lines of evidence demonstrating the activation and
alteration of motor-related brain regions by stimulant
drugs67. Given that increased activation in motor path-
ways has been linked to stimulant drug-induced sensiti-
zation24,68 and underlying progressive recruitment of
sensorimotor and dorsal striatal regions69,70 in stimulant
drug users (an effect shown to persist for several months
following stimulant drug exposure69), it is tempting to
speculate that increased activation seen in stimulant-
using individuals in the current study might reﬂect
enhanced ventral-to-dorsal progression of striatal
recruitment facilitated by stimulant drugs71,72.
In light of previous reports on striatal function during the
MID-task, we predicted blunted ventral striatal activation in
stimulant drug users25,49. However, unlike the robust
changes in motor circuitry, we found no measurable effects
of stimulant drug use on task-related activation patterns
within the ventral striatum–widely considered to be a
neural correlate for reward anticipation34–even though this
structure was strongly activated during the MID-task
performance in all participants. It is noteworthy that task-
related differences in ventral striatal activation following
stimulant abuse have not been consistently repor-
ted25,61,62,73–77, which may be due to variations in sample
characteristics and experimental design78 such as the
recency of drug use79. Accordingly, although blunted acti-
vation in the ventral striatum is frequently reported in
abstinent stimulant-dependent individuals63,80–82, such dif-
ferences are often not observed76,77,83,84 in active drug users,
consistent with present ﬁndings.
Effects of familial risk on reward processing
Similar to the effects of stimulant drug use, familial risk
had no measurable effect on MID-task performance.
However, unlike stimulant drug use, familial risk also had
no measurable impact on task-related brain activation in
reward-related brain regions. This observation is consistent
with previous fMRI studies in individuals with familial
risk85–87. Our data suggest that familial risk is conveyed in
task-related corticostriatal functional connectivity (Fig. 3c).
Speciﬁcally, we observed altered functional connectivity
between the putamen and the ACC, OFC, and mPFC–brain
regions associated with the processing of monetary
rewards34,35–in participants with familial risk, irrespective
of whether they used stimulant drugs.
These ﬁndings are interesting given a bulk of research
demonstrating functional and structural pathways
between the ventral putamen and frontal regions such as
the mPFC, OFC, and ACC88,89. Accordingly, the ventral
putamen is involved in a frontal network that is recruited
during response monitoring or goal-directed control
required for the processing of reward90. These observa-
tions strongly suggest that the putamen, in addition to
being a motor structure, is involved in higher-level cog-
nitive functions56. In particular, the OFC, mPFC, and
ACC have been implicated in an inhibition network
consisting of cortical motor regions and basal ganglia
structures, including the putamen91,92. It is possible that
aberrant functioning of these corticostriatal networks
confers vulnerability on individuals with family risk,
altering higher-cognitive functioning and increasing their
susceptibility to the development of addiction.
Abnormal task-related corticostriatal functional con-
nectivity demonstrated here, and elsewhere, in both addic-
ted93 and vulnerable adolescents86, adds to the body of
evidence supporting endophenotypes in striatal and pre-
frontal cortical brain regions. Prior ﬁndings of enlarged
putamen12 and altered prefrontal cortical white matter in
sibling pairs43, along with the present ﬁndings, suggest that
such endophenotypes may consist of both structural and
functional striatal abnormalities. Taken together with the
effects of stimulant drug use, our results suggest that sti-
mulant drug addiction may impact the function of struc-
tures contained within brain pathways already compromised
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by familial risk, thereby exacerbating pre-existing functional
deﬁcits, perhaps leading to the development of addiction.
Interaction between stimulant drug use and familial risk
during reward processing
In the present study, we observed an interaction on
task-related functional connectivity between the putamen
and the precentral and postcentral gyri in non-addicted
stimulant drug users and non-stimulant drug users with
familial risk. This interaction was characterized by an
increase in functional connectivity strength to the pre-
central and postcentral gyri, which are involved in motor
and somatosensory functions, possibly indicating com-
pensatory or resiliency mechanisms. Potential resilience,
in the form of low sensation-seeking traits, has been
previously reported in unaffected siblings44,48, which may
reﬂect lack of motivation to initiate drug use. In previous
studies, individuals with familial risk demonstrated
increased striatal functional connectivity strength to
attention- and motor-related structures, including the
precentral and postcentral gyri, during reward anticipa-
tion86. However, such studies were unable to determine
whether such changes represented addiction risk or resi-
lience. Here we provide additional evidence that func-
tional connectivity strength between striatal regions and
motor-related structures when anticipating a reward may
represent a mechanism for resilience in individuals with
either familial risk or risks associated with the use of
stimulants. Such changes in motor-related structures may
confer increased motor control, allowing these resilient
individuals to cope with/resist the addictive properties of
drug use or mitigate pre-existing impulsive tendencies94.
Limitations and implications
To the best of our knowledge, the present results
demonstrate for the ﬁrst time distinct effects of stimulant
drug use and familial risk on task-related putamen acti-
vation and functional connectivity of the putamen,
respectively. Our study beneﬁtted from a rigorous statis-
tical approach and was conducted in a large sample with
relatively stringent statistical thresholds. However, we also
acknowledge several limitations of this study. Potentially
confounding inﬂuences in stimulant drug-taking experi-
ences and familial risk in the selected statistical model
were addressed using additional post-hoc analyses, which
are not always ideal for controlling for differences in
incidental variables as such differences may indicate dif-
ferences in other relevant variables that were not assessed.
We also acknowledge that stimulant drug users were
separated based on their familial risk, yet familial risk is
only one, albeit important, risk factor for the development
of addiction. Other possible risk factors may encompass
neurobiological or socioeconomic differences that may
exist between dependent and non-dependent stimulant
drug users45,46,95,96, rendering some individuals more
vulnerable to developing addiction than others. Further-
more, the design of our study does not allow for the
identiﬁcation of the speciﬁc aspects of familial or drug use
risks responsible for the current ﬁndings.
Reward-related striatal function has been associated
with measures of addiction recovery and rehabilitation97.
In the absence of medically proven pharmacological
treatments, therapeutic interventions for stimulant drug
addiction currently rely on psychosocial and family-based
approaches98, which focus on previously identiﬁed
familial environmental risk-factors28 but do not take into
account associated neurobiological risk-factors. Embed-
ding the emerging knowledge of neurobiological vulner-
ability factors that are shared between family members
into family-based interventions may increase therapeutic
efﬁcacy, perhaps by facilitating the delivery of prevention
and intervention programs during childhood and adoles-
cence. Of particular relevance, we identiﬁed altered cor-
ticostriatal pathways as a candidate endophenotype for
stimulant drug addiction. To fully realize the implications
of this result, future research should attempt to char-
acterize the behaviors supported by these pathways, and
how they contribute to the development of addiction.
Thus, the identiﬁcation of endophenotypes, as well as
resiliency mechanisms, will contribute to the synthesis of
intervention strategies and the development of targeted
therapies by providing distinct neural biomarkers that
may help predict treatment response or successful/
unsuccessful abstinence in addiction.
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